A phase II trial of gallium nitrate (NSC #15200) in previously treated ovarian carcinoma. A Gynecologic Oncology Group Study.
Twenty-six evaluable patients with advanced or recurrent epithelial ovarian cancer were treated with 750 mg/m2 of gallium nitrate every three weeks. All patients had prior cisplatin chemotherapy. One patient had a complete response (3.8%), two patients had partial responses (7.7%), and six patients had stable disease (23.1%). The 95% upper confidence bound for response is 27.2%. The major toxicity was nausea and vomiting which was modest, and anemia, which was moderate to severe. Myelosuppression was minimal. Gallium nitrate has modest activity in previously treated patients with epithelial ovarian cancer.
Malfetano
J H
JH
Department of Obstetrics and Gynecology, Albany Medical Center, New York.
Blessing
J A
JA
Adelson
M D
MD
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005708:Gallium / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012074:Remission Induction / Q000379:methods; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D005708:Gallium; C027235:gallium nitrate